Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibImproved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?Delivery of curcumin by directed self-assembled micelles enhances therapeutic treatment of non-small-cell lung cancer.DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cellsAxitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progressionThe preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesotheliomaSynergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.Sorafenib in non-small cell lung cancer.The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution.New treatment options for lung adenocarcinoma--in view of molecular background.Efficacy of motesanib diphosphate in non-small-cell lung cancer.Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?Strategies targeting angiogenesis in advanced non-small cell lung cancer.Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation.Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT.Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo.Targeted drugs for systemic therapy of lung cancer with brain metastases.Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.
P2860
Q22305863-C43F2F7C-4A1F-4DC1-804C-2D3E5028B696Q26775394-63971E5D-64B1-42B8-87C5-68591B38D518Q26995204-150DB452-D9CC-4FC9-B017-0FD3085977D9Q30316339-7C309A5E-C195-4A1B-A04A-7AB120FE2AFEQ33553570-72D46157-BA59-48A4-B928-943AC7EB3E90Q33878937-6EC75D7F-CAE6-40F8-A56E-1998734DF503Q34092023-73054A18-D99E-4E91-B7D6-4316B182850FQ34294188-1AF471E4-C226-4D87-955F-B8F2D9E5BF3CQ34353920-18709395-3232-41EB-BC41-007F5421ADA5Q34865296-396EE072-EC6E-428A-A792-1ABDA3E89EE7Q35786366-421D80C9-2A4C-4C2A-B010-91C1FEE4FE1CQ37031569-1C90CD3E-7868-4E5F-A43C-789DEF30C601Q37611680-92BA560D-4B2C-44D8-A54E-B53443002783Q37692451-82D8959E-9698-4EC0-964C-CCA67F07C7A2Q38020917-647BC936-A415-4318-BA73-C790A2FBEDE8Q38061626-6320E4CF-4E8F-43E9-8C9E-5B51D36587BAQ38168761-47AA5D41-5055-4617-84A0-1E5B58CD8BD6Q38230556-EC7643E0-38F7-4BBE-A63B-A9F8EC772D24Q38292799-FE64701D-470B-46CA-B5C1-ADF22D46B4D7Q38728552-A2BC5CC3-2718-4EA5-8F17-5E9C3AE9E5FCQ38763633-0399BFF4-F362-418E-A7B4-C1E4DF679DC5Q41593429-404950BA-4235-4B9B-BD26-F81682EF6757Q41597464-2D59B040-71B7-4D6E-BE4C-61EF898AA9D9Q41890760-0623EB67-CF92-4A03-AB13-4C3106E8E1B3Q47107773-4D196E21-7D7F-4782-ACF5-2368CC53F477Q47166468-C4FCC172-7967-43B0-9548-8536BE8F849AQ50052820-128749B7-6F9C-4D15-83B8-93AB8FF59742Q53056691-A2EDE2CA-2552-43E1-BAB0-9C380068A141
P2860
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiangiogenic agents in the m ...... d now and where are we headed?
@en
type
label
Antiangiogenic agents in the m ...... d now and where are we headed?
@en
prefLabel
Antiangiogenic agents in the m ...... d now and where are we headed?
@en
P2093
P2860
P356
P1476
Antiangiogenic agents in the m ...... d now and where are we headed?
@en
P2093
Charu Aggarwal
George Simon
Neeta Somaiah
P2860
P304
P356
10.4161/CBT.19594
P577
2012-03-01T00:00:00Z